Friday, 29 October 2021

Australia's most trusted
source of pharma news

Friday, 29 October 2021

AbbVie in nasty biosims brawl

 Posted 12 October 2021 AM

An ugly battle has erupted over AbbVie's blockbuster Humira with the company branded as 'un-Australian' and put on notice for 'perceived anti-competitive' behaviour as it attempts to continue its dominance in the adalimumab market.

The Australian Biosimilars Academy (ABA), headed by former National President of the Pharmacy Guild George Tambassis, has lashed out in a scathing attack on AbbVie, accusing the company of putting profits before patients in its efforts to continue its hold on the adalimumab market, even though the patent for Humira has now expired.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read. If you don't have a password, just enter your email address and then click Login.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.